Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: An immunohistochemical study

Breast Cancer Research and Treatment

Volumn 130, Issue 2, 2011, Pages 457-463

  Powe, D G ^a   Voss, M J ^b   Habashy, H O ^a   Zanker K S ^b   Green, A R ^a   Ellis, I O ^a   Entschladen, F ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

Adrenergic antagonist; Adrenergic receptor; Adrenoceptor; Breast cancer; Prognosis, treatment

Indexed keywords

ALPHA 1B ADRENERGIC RECEPTOR; ALPHA 2C ADRENERGIC RECEPTOR; ANTINEOPLASTIC AGENT; BETA 2 ADRENERGIC RECEPTOR; CYTOKERATIN 14; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; TAMOXIFEN;

ADULT; AGED; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER GRADING; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SYSTEMIC THERAPY; TISSUE MICROARRAY; TREATMENT OUTCOME; TUMOR RECURRENCE; TUMOR VOLUME;

ADULT; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, ADRENERGIC, BETA-2; RECEPTORS, ESTROGEN; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 82955197460     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1371-z     Document Type: Article

References (35)

1. Surveillance Epidemiology and End Results. http://seer.cancer. gov/publications/
2. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Aksien LA et al (2000) Molecular portraits of human breast tumours. Nature 406(6797): 747-752
3. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS et al (2001) Gene expression patterns of breast carcinomas distinguish tumor sub-classes with clinical implications. Proc Natl Acad Sci USA 98(19):10869-10874 (Pubitemid 32878711)
4. Johnston SRD (2009) Enhancing the efficacy of hormonal agents with selected targeted agents. Clin Breast Cancer 9:S28-S36
5. Engel J, Eckel R, Kerr J, Schmidt M, Furstenberger G, Richter R, Sauer H, Senn HJ, Holzel D (2003) The process of metastasisa-tion for breast cancer. Eur J Cancer 39(12):1794-1806
6. Entschladen F, Drell TL, Lang K, Joseph J, Zaenker KS (2004) Tumour-cell migration, invasion, and metastasis: navigation by neurotransmitters. Lancet Oncol 5(4):254-258 (Pubitemid 38391223)
7. Entschladen F, Drell TL, Lang K, Joseph J, Zaenker KS (2005) Neurotransmitters and chemokines regulate tumor cell migration: potential for a new pharmacological approach to inhibit invasion and metastasis development. Curr Pharm Des 11(3):403-411 (Pubitemid 40277866)
8. Masur K, Niggemann B, Zaenker KS, Entschladen F (2001) Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers. Cancer Res 61(7):2866-2869 (Pubitemid 32691927)
9. Lang K, Drell TL, Lindecke A, Niggemann B, Kaltschmidt C, Zaenker KS, Entschladen F (2004) Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int J Cancer 112(2):231-238 (Pubitemid 39244363)
10. Drell TL, Joseph J, Lang K, Niggemann B, Zaenker KS, Ents-chladen F (2003) Effects of neurotransmitters on the chemoki-nesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res Treat 80(1):63-70 (Pubitemid 36851285)
11. Palm D, Lang K, Niggemann B, Drell TL, Masur K, Zaenker KS, Entschladen F (2006) The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited bybeta-blockers. Int JCancer 118(11):2744-2749 (Pubitemid 43673352)
12. Sood AK, Bhatty R, Kamat AA, Landen CN, Han L, Thaker PH, Li Y, Gershenson DM, Lutgendorf S, Cole SW (2006) Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res 12(2):369-375 (Pubitemid 43166123)
13. Dorn GW, Liggett SB (2008) Pharmacogenomics ofbeta-adren-ergic receptors and their accessory signaling proteins in heart failure. CTS Clin Transl Sci 1(3):255-262
14. Rosini M, Bolognesi ML, Giardina D, Minarini A, Tumiatti V, Melchiorre C (2007) Recent advances in alpha(1)-adrenoreceptor antagonists as pharmacological tools and therapeutic agents. Curr Top Med Chem 7(2):147-162 (Pubitemid 46062387)
15. Harris AM, Warner BW, Wilson JM, Becker A, Rowland RG, Conner W, Lane M, Kimbler K, Durbin EB, Baron AT et al (2007) Effect of alpha 1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study. J Urol 178(5):2176-2180 (Pubitemid 47538576)
16. Algazi M, Plu-Bureau G, Flahault A, Dondon MG, Le MG (2006) Is beta-blocker treatment associated with a decrease in the risk of cancer. Lett Drug Des Discov 3(9):653-661 (Pubitemid 44577159)
17. Abdel-Fatah TMA, Powe DG, Ball G, Reis JS, Ellis IO (2009) The need for a biological grading system and its relationship to the current Nottingham histological grading system (NGS). EJC Suppl 7(2):264-265
18. El-Rehim D, Ball G, Pinder S, Rakha E, Paish C, Robertson J, Macmillan D, Blamey R, Ellis I (2005) High throughput protein expression analysis using tissue microarray technology of a large well -characterised series identifies biologically distinct classes of breast cancer confirming recent c DNA expression analyses. Int J Cancer 116(3):340-350 (Pubitemid 40993329)
19. El-Rehim DMA, Ball G, Pinder S, Ellis IO (2004) Molecular classification ofbreast carcinoma based on the protein expression immunoprofiles. J Pathol 204:3A-4A
20. Habashy HO, Powe DG, Rakha EA, Ball G, Paish C, Gee J, Nicholson RI, Ellis IO (2008) Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance. Eur J Cancer 44(11):1541-1551
21. Mc Shane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) REporting recommendations for tumor MARKer prog-nostic studies (REMARK). Breast Cancer Res Treat 100(2):229-235 (Pubitemid 44631925)
22. Luthy IA, Bruzzone A, Pinero CP, Castillo LF, Chiesa IJ, Vaz-quez SM, Sarappa MG (2009) Adrenoceptors: non-conventional target for breast cancer? Curr Med Chem 16(15):1850-1862
23. Badino G, Novelli A, Girardi C, Carlo FD (1996) Evidence for functional beta-adrenoceptor subtypes in CG-5 breast cancer cell. Pharmacol Res 33(4-5):255-260 (Pubitemid 26383686)
24. Marchetti B, Fortier MA, Poyet P, Follea N, Pelletier G, Labrie F (1990) Beta-adrenergic receptors in the rat mammary gland during pregnancy and lactation\-characterization, distribution, and coupling to adenylate cyclase. Endocrinology 126(1):565-574 (Pubitemid 20037190)
25. Slotkin TA, Zhang JA, Dancel R, Garcia SJ, Willis C, Seidler FJ (2000) Beta-adrenoceptor signaling and its control of cell repli-cation in MDA-MB-231 human breast cancer cells. Breast Can-cer Res Treat 60(2):153-166 (Pubitemid 30307475)
26. Vandewalle B, Revillion F, Lefebvre J (1990) Functional adrenergic receptors in breast cancer cells. J Cancer Res Clin Oncol 116(3):303-306
27. Shang ZJ, Liu K, Liang DF (2009) Expression of beta(2)-adrenergic receptor in oral squamous cell carcinoma. J Oral Pathol Med 38(4):371-376
28. Draoui A, Vandewalle B, Hornez L, Revillion F, Lefebvre J (1991) Beta-adrenergic receptors in human breast cancer\-char-acterization and correlation with progesterone and estradiol receptors. Anticancer Res 11(2):677-680
29. Schuller HM (2007) Neurotransmitter receptor-mediated signal-ing pathways as modulators of carcinogenesis. Neuronal Act Tumor Tissue 39:45-63
30. Lancashire L, Powe D, Reis-Filoh J, Rakha E, Lemetre C, Wei-gelt B, Abdel-Fatah T, Green A, Mukta R, Blamey R et al (2010) A validated gene expression profile for detecting clinical outcome in breast cancer using artificial neural networks. Breast Cancer Res Treat 120(1):83-93
31. Al-Wadei HA, Al-Wadei MH, Schuller HM (2009) Prevention of pancreatic cancer by the beta-blocker propranolol. Anti-Cancer Drugs 20(6):477-482
32. Powe DG, Habashy HO, Voss MH, Zaenker KS, Green AR, Ellis IO, Entschladen F (2010) Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 1(7):628-638
33. Hui HX, Fernando MA, Heaney AP (2008) The alpha(1)-adren-ergic receptor antagonist doxazosin inhibits EGFR and NF-kappa B signalling to induce breast cancer cell apoptosis. Eur J Cancer 44(1):160-166 (Pubitemid 350256942)
34. Lowe FC (2004) Role of the newer alpha(1)-adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-rela-ted lower urinary tract symptoms. Clin Ther 26(11):1701-1713 (Pubitemid 40089486)
35. Chiu G, Connolly PJ, Middleton SA, Li SJ, Pulito V, Liu JC, Baxter EW, Reitz AB (2008) Alpha(1a/1d)-selective adrenergic receptor antagonists for the treatment of benign prostatic hyper-plasia/lower urinary tract symptoms. Expert Opin Therap Pat 18(12):1351-1360